

XIII INTERNATIONAL WORKSHOP ON LOWER GENITAL TRACT PATHOLOGY

HPV Disease and Cervical Cancer:
Summing Up

ROME
APRIL 12-13 2018

COURSE DIRECTORS

Philip Davies
Antonio Frega
Cesare Gentili



Course Directors

P. Davies
A. Frega
C. Gentili

International Scientific Committee

A. Ciavattini - Italy
R. De Vincenzo - Italy
J. Dillner - Sweden
D. French - Italy
A. Lukic - Italy
B. Moscicki - U.S.
K.U. Petry - Germany
W. Prendiville - France

Organising Secretariat



Adria Congrex
Via Sassonia, 30 - 47922 Rimini
Tel. 0541 305811
c.imola@adriacongrex.it

PROGRAM AT A GLANCE

Thursday, April 12 2018

TIME	ROOM A	ROOM B
08.30 – 08.50	OPENING LECTURE	
08.50 – 10.20	HPV INFECTION AND CARCINOGENESIS	
10.20 – 11.00	EPIDEMIOLOGY OF CERVICAL CANCER AND HPV INFECTION	
11.00 – 11.30	BREAK	
11.30 – 13.00	CERVICAL SCREENING	
13.00 – 13.30	LECTURE SPONSORED BY FARMITALIA	
13.30 – 14.00	LECTURE SPONSORED BY BIOSTILOGIT	
14.00 -14.30	LUNCH	
14.30 - 15.40	CERVICAL SCREENING: THE NEW CHALLENGES	UPDATES IN MOLECULAR BIOLOGY
15.40 – 16.50	HPV POSITIVE, WHAT NEXT?	UPDATES IN CYTOPATHOLOGY
16.50 – 17.10	BREAK	
17.10 – 18.00	COLPOSCOPY IN THE ERA OF HPV VACCINATION AND HPV SCREENING	ASK THE EXPERT
18.00 – 18.55	NONCOMPLIANCE WITH REFERRAL TO COLPOSCOPY	

Friday, April 13 2018

TIME	ROOM A	ROOM B
08.30 – 10.40	VACCINATION	FREE COMMUNICATIONS
10.40 – 11.10	BREAK	
11.10 – 13.00	ENSURING THE SAFETY AND EFFECTIVENESS OF COLPOSCOPY	FREE COMMUNICATIONS
13.00 – 13.30	LECTURE SPONSORED BY SHIONOGI	
13.30 -14.30	LUNCH	
14.30 – 15.40	PUBLIC EDUCATION AND COVERAGE RATES	PAP SMEAR: NEVER SAY NEVER AGAIN
15.20 – 17.20	THE CERVICAL CYTOPATHOLOGY IN THE HPV TESTING ERA	THE CERVICAL CYTOPATHOLOGY IN THE HPV TESTING ERA
16.30 – 17.40	MISCELLANY	
17.20 – 18.20	AWARDS AND CONCLUSIONS	

FACULTY

M. Barbero - Italy
M. Benevolo - Italy
A. Biamonti- Italy
F. Boselli - Italy
E. Carico - Italy
D. Caserta - Italy
A. Castanon - U.K.
M. Cruickshank - U.K.
P. Davies - Belgium
R. De Vincenzo - Italy
F. De Seta - Italy
J. Dillner - Sweden
L. Dillner - Sweden
J. Doorbar - U.K.
E. Giarnieri - Italy
M.R. Giovagnoli - Italy
M. Goodmam - U.S.
W. Huh - U.S.
L. Mariani - Italy
B. Moscicki - U.S.
P. Martin Hirsch - U.K.
G. Negri - Italy
M. O'Connor - Ireland
M. Peroni - Italy
K.U. Petry - Germany
W. Prendiville - France
W. Ricciardi - Italy
G. Scambia - Italy
R. Senatori- Italy
F. Sopracordevole - Italy
U. Tabuica - Moldova
F. Torcia - Italy
A. Venuti - Italy
J. Waller - U.K.
C. Zanardi - Italy

PROGRAM

Thursday 12 / Friday 13
April 2018

Thursday 12 April 2018

Morning

8.00 Registration

8.20 Welcome P. Davies.-A. Frega - C. Gentili

ROOM A (Plenary session)

8.30 Opening Lecture

Chairman: G. Scambia

HPV infection and carcinogenesis: a public health perspective.
W. Ricciardi

8.50-10.20 HPV infection and Carcinogenesis

Chairpersons: P. Davies - A. Venuti

8.50-9.10 Human papillomavirus infection and the induction of neoplasia.
J. Doorbar

9.10-9.30 The natural history of HPV infection in screening age women: do we have enough data to really understand what is happening in this age group?
B. Moscicki

9.30-9.50 Persistent vs repeated infections: can we tell the difference and does it make a difference to cervical carcinogenesis?
J. Doorbar

9.50-10.10 New hot topics. HPV in non HIV immunocompromised men and women: screening and management.
B. Moscicki

10.10-10.20 Discussion

10.20-11.00 Epidemiology of Cervical Cancer and HPV Infection

Chairpersons: A. Castanon – A.Lukic

10.20-10.40 Cervical cancer trends around the world: are we making a difference?
P. Davies

10.40-11.00 HPV vaccination and its impact on HPV infection rates around the world.
J. Dillner

11.30-13.00 Cervical Screening

Chairpersons: J. Dillner - C. Gentili

11.30-11.50 The current status of cervical screening programmes around the world: are we making progress where it is needed most or just improving the best?

M. Goodman

10.50-12.10 HPV testing for primary screening: who is doing what?
A. Castanon

12.10-12.30 The latest data from the HPV primary screening programmes: the benefits and the challenges that remain to be solved.
M. Goodman

12.30-12.50 Cervical screening: is there still a role for the Pap test?
P. Davies

12.50-13.00 Discussion

13.00 - 13.30 LECTURE SPONSORED BY FARMITALIA - NON ECM

Vulvovaginitis & HPV infection: diagnostic and therapeutic issues

M. Sansone

13.30 -14.00 LECTURE SPONSORED BY BIOSTILOGIT - NON ECM

Ellacid acid/acetogenins annonaceus supplement: effects on cervical HPV related preneoplastic lesions

M. Le Donne

Afternoon

ROOM A

14.30-15.40 Cervical Screening: the New Challenges

Chairpersons: A. Biamonti - U. Petry

14.30-14.50 Estimating the impact of HPV primary screening and HPV vaccination on cervical cancer rates.

A. Castanon

14.50-15.10 The evolution of HPV testing in the U.S
W. Huh

15.10-15.30 HPV screening recall and follow-up recommendations: do doctors stick to the rules?
M. Goodman

15.30-15.40 Discussion

15.40-16.50 HPV Positive: what Next?

Chairpersons: M. Cruickshank - M. Peroni

15.40-16.00 HPV positive: what are the triage options and their associated risks
K.U. Petry

- 16.00-16.20 How does HPV status affect the treatment of low-grade cervical disease?
P. Martin Hirsch
- 16.20-16.40 Persistent HPV Infection without colposcopically visible cervical disease: how common and what is the appropriate follow-up?
K.U. Petry
- 16.40-16.50 Discussion

17.05-18.00 Colposcopy in the Era of HPV Vaccination and HPV Screening

Chairpersons: W. Huh - F. Sopracordevole

- 17.05-17.20 The implications of HPV vaccination for the practice of colposcopy.
M. Cruickshank
- 17.20-17.35 HPV primary screening: will this affect the accuracy of colposcopy?
P. Martin Hirsch
- 17.35-17.50 Should colposcopists be re-trained to deal with the realities of the HPV era
K.U. Petry
- 17.50-18.00 Discussion

18.00-18.55 Noncompliance with Referral to Colposcopy

Chairpersons: P. Martin Hirsch - C. Zanardi

- 18.00-18.15 Noncompliance with colposcopy referral: the extent of the problem in different countries.
U. Tabuica
- 18.15-18.30 Why do women decide not to go to colposcopy?
M. Cruickshank,
- 18.30-18.45 Understanding and reducing the adverse psychological impact of colposcopy
J. Waller
- 18.45-18.55 Discussion

ROOM B

14.30-16.00 Updates in Molecular Biology

Chairpersons: D. French - A. Venuti

- 14.30-14.50 Latent papillomavirus infections: the role of the HPV test.
J. Doorbar
- 14.50-15.10 Getting around in the molecular testing jungle: what clinicians and pathologists should know to properly interpret the results.
L. Dillner

- 15.10-15.30 Investigating diagnostic problems of CIN1 and CIN2 associated with high-risk HPV by combining the novel molecular biomarker PanHPVE4 with P16INK4a.
J. Doorbar
- 15.30-15.50 The role of cytology and HPV genotyping in screening for anal cancer.
B. Moscicki
- 15.50-16.00 Discussion

16.00-16.50 Updates in Cytopathology

Chairpersons: M. Benevolo – E. Giarnieri

- 16.00-16.20 Is the new Bethesda system tailored for HPV screening and molecular diagnosis?
M.R. Giovagnoli
- 16.20-16.40 Cytology triage: what molecular testing cannot provide.
G. Negri
- 16.40-16.50 Discussion

17.10-18.45 Ask the Experts

Coordinators: P. Davies- A. Frega- C. Gentili

Open forum: what would you like to ask a panel of experts?
R. De Vincenzo, J. Dillner, G. Negri, M. O'Connor, W. Prendiville

Friday 13 April 2018

..... Morning

ROOM A (Plenary session)

8.30-10.40 Vaccination

Chairpersons: M. Cruickshank - A. Lukic

8.30-8.50 HPV vaccination around the world today: the programs and the coverage rates.

J. Dillner

8.50-9.10 HPV vaccination: long-term efficacy and protection. What are the data?

R. De Vincenzo

9.10-9.30 Screening in vaccinated and unvaccinated women: are two algorithms necessary and if so how do we implement them?

M. O'Connor,

9.30-9.50 HPV vaccination of boys: who is doing what?

J. Dillner

9.50-10.10 Improving HPV vaccination coverage: what works and what doesn't.

J. Waller

10.10-10.30 The nonavalent HPV vaccine: what changes?

L. Mariani

10.30-10.40 Discussion

11.10-13.00 Ensuring the Safety and Effectiveness of Colposcopy

Chairpersons: A.Ciavattini - M. O'Connor

11.10-11.30 Adverse sequelae after the treatment of CIN: an international comparison

P. Martin Hirsch

11.30-11.50 Treatment of cervical pre-cancer: current best practice

W. Prendiville

11.50-12.05 Colposcopy training: the similarities and differences across Europe.

M. Cruickshank

12.05-12.20 Training colleagues in middle income countries

W. Prendiville

12.20-12.35 Quality assurance of colposcopy: the European perspective

K.U. Petry

12.35-12.50 Quality assurance of colposcopy: the American perspective.

W. Huh

12.50-13.00 Discussion

13.00-13.30 LECTURE SPONSORED BY SHIONOGY - NON ECM
Papilocare vaginal gel innovative therapy for the treatment of LSIL
P. Inghirami

ROOM B

8.30-11.00 Free Communication

Chairpersons: A. Biamonti- R. Barbero – E.Carico

HPV INFECTION AND CANCEROGENESIS

8.30 – 8.37 Case-control study on the efficacy of carboxymethylbetaglucan-lactoferrin association in women with high-risk Human Papillomavirus (HPV) uterine cervical infection

A.A. Criscuolo, E. Guri, M. Ciotti, F. Sesti, E. Piccione

CERVICAL SCREENING

8.37 – 8.44 Reducing unnecessary colposcopy by risk discrimination. HPV genotyping with NILM or low-grade cytology in screening paradigms: systematic review

J. Andrews

8.44-8.58 Risk of invasive lesions in cytologically atypical glandular cells (AGC) on conventional Pap Test: follow up study

E. Isidoro

8.51-8.58 Primary cervical cancer screening with a 5-type HPV e6/e7 mRNA test: results of 10 years follow-up

S.W. Sørbye, A.Rad, F.E. Skjeldestad

8.58-9.05 HPV test in triage of ASC-US/LSIL - the risk of CIN3+ in 5-type HPV E6/E7 mRNA negative women

S.W. Sørbye, M.M. Slettebak, F.E. Skjeldestad

9.05-9.12 Cytology and 3-type HPV e6/e7 mRNA co-testing in women 25-33 years

S.W. Sørbye, F.E. Skjeldestad FE

9.12-9.19 Detection of CIN2+ in women with normal cytology - the added value of a 3-type HPV E6/E7 mRNA test

S.W. Sørbye, B. Westre, A. Giske, H. Guttormsen, F.E. Skjeldestad

9.19-9.29 Discussion

COLPOSCOPY

9.29-9.36 Smartscopy: the speculoscopy applied to the smartphone can be an efficient alternative to the traditional one?

C. Bondi, A. Palmeri, M. Maramai, F. Casabona

9.36-9.43 Endocervicoscopy: a new imaging technique and its accuracy in studying cervical intraepithelial lesion

N. De Rosa, G. Lavitola, M.Palma, R.Gallo, M.C Pagliuca,

C. Di Filippo, G. Bifulco

- 9.43-9.50 How to use a low cost CCD camera for hysteroscopy and colposcopy: our "all-in-one" device
M. Maramai, C. Bondi, A. Palmeri, F. Casabona
- 9.50-9.57 LSIL: colposcopic pictures and indication to direct biopsy. A study of the SICPCV
M.Serri, F. Sopracordevole, P.Garutti, M. Fallani, B. Gardella, P.Scirpa, M.T. Schettino, A. Del Fabro, A. Pieralli, F. Ravennati, S.Montori, R.Agrusti, M.Papiccio, A.C.Boschi, M.R. Primieri, F. Cigolot, A. Ciavattini
- 9.57-10.04 Evidence for clinical utility of extended HPV genotyping in persistence tracking and follow-up after abnormal results and colposcopy
J. Andrews
- 10.04-10.14 Discussion

MISCELLANY

- 10.14-10.21 Lymphoma of the lower female genital tract
R. Sparic, A. Dobrosavljevic, J. Stulic, L. Nejkovic
- 10.21-10.28 Tubulosquamous polyp in vagina together with VAIN II/III
R. Sparić, J.Stulic, A. Dobrosavljevic, L. Nejkovic
- 10.28-10.40 Discussion

11.10 – 13.30 Free Communications

Chairpersons: D. French - E. Giarnieri - R. Senatori

EPIDEMIOLOGY OF CERVICAL CANCER AND HPV INFECTION

- 11.10-11.17 The risk of cervical atypia in oral contraceptive users
I. Adhikari, T.Eriksson, T. Luostarinen, M.Lehtinen, D.Apter
- 11.17-11.24 Countries of Eastern Europe and Central Asia: the situation of HPV infection in HIV-positive women
A.A. Popova, O.Y. Shipulina, M.O. Deulina
- 11.24-11.31 Prevalence of cervical HPV lesions in patients with bowel inflammatory diseases in immunosuppressive treatment and cervical screening: multidisciplinary management experience in a referral center
C.Ricci, F.Scaldaferri, F. Colombo, A. Gasbarrini, G. Scambia, R. De Vincenzo
- 11.31-11.38 Role of vaginal TIAB in cervical reepithelialisation and high-risk HPV clearance in patients with low-grade cervical lesions
C.Ricci, M.T.Evangelista, G. Scambia, R. De Vincenzo
- 11.38-11.45 HPV-HR prevalence and type distribution in women with NILM or HSIL Pap smear in Russia.
O.Y. Shipulina, M.Y. Dmitryukova, G.V.Leshkina
- 11.45-11.55 Discussion

MOLECULAR BIOLOGY AND CYTOPATHOLOGY

- 11.55-12.02 The risk of developing a CIN2+ lesion in women with HPV16 and 18, versus women with other HPV types: follow-up study
E. Isidoro, U. Wiesenfeld, M. Di Napoli, A. Romano, J. Dobric, C. Biagi, F. Variola, S.Tomasi, D.Santon, S.Dudine, F. Giudici, L. Di Bonito, F. Zanconati
- 12.02-12.09 Mesenchymal stem cells from cervix: what is about age and inflammation?
G. Delli Carpini, M. Orciani, M. Caffarini, R. Lazzarini, S. Guizzardi, D. Tsiroglou, R. Di Primo, A. Ciavattini
- 12.09-12.16 Molecular study of HPV-related oropharyngeal carcinoma
G. Ferrario, P. Morbini, P. Alberizzi, M. Benazzo
- 12.16-12-23 HR-HPV negative cases of cytological HSIL and additional testing results for low and unknown risk types.
G.V. Leshkina, O.Y. Shipulina, T.N. Romanyuk
- 12.23-12.30 DNA HPV testing and diagnostic cytopathology for oral cancer screening
Navone R., Amodeo E., Lapucci C., Crò F., Pentenero M., Gandolfo S.
- 12.30-12.37 Expression of E6/E7 HPV-DNA, HPV-mRNA and colposcopic features in management of CIN2/3 during pregnancy
C. Leone, D. French, M. Pavone, A. Frega, D. Caserta
- 12.37-12.47 Discussion

TREATMENT AND FOLLOW-UP

- 12.47-12.54 Evidence for clinical utility of extended HPV genotyping in Test of Cure after treatment of CIN2+
J. Andrews
- 12.54-13.01 Radiofrequency and poration for the treatment of HPV genital warts: a case report
C. Catalisano
- 13.01-13.08 Role of "close" negative endocervical margin in treatment failure after cervical excision for cervical intraepithelial neoplasia: a retrospective study
G. Delli Carpini, A. Del Fabro, L. Alessandrini, M. Buttignol, V. Canzonieri, A. Cagnacci, F. Sopracordevole, A. Ciavattini
- 13.08-13.15 LLETZ in woman of reproductive age diagnosed with squamous intraepithelial lesions: the problem of specimen artifacts
R.Sparic, S.Kadija, R. Stefanovic, L.Jovanovic, T. Janjic, J.Bila, M. Berisavac
- 13.15-13.25 Discussion

..... **Afternoon**

ROOM A**14.30-15.40 Public Education and Coverage Rates****Chairpersons:** F.Boselli - W.Prendiville

- 14.30-14.45 Social and psychological impact of HPV testing in cervical screening.
J. Waller
- 14.45-15.00 Reaching under- or never-screened women: is self-sampling the answer?
L. Dillner,
- 15.00-15.15 The impact of HPV vaccination on cervical cancer screening coverage: are the predictions proving to be true?
M. Cruickshank
- 15.15-15.30 HPV vaccination for adolescents, Pap screening for under-30's, HPV screening for over 30's: how can we effectively communicate all this to ensure high programme participation?
M. O'Connor
- 15.30-15.40 Discussion

15.40-16.30 HPV and Vaginal Infection**Chairpersons:** A. Biamonti - U. Tabuica

- 15.40-15.55 The role of vaginal microbiome in HPV infection and disease.
B. Moscicki
- 15.55-16.05 Chlamydia trachomatis infection: epidemiology, treatment and its role in HPV disease
F. De Seta,
- 16.05-16.20 The effect of intrauterine devices on acquisition and clearance of human papillomavirus
B. Moscicki
- 16.20-16.30 Discussion

16.30-17.40 Miscellany**Chairpersons:** R. Senatori- F. De Seta

- 16.30-16.45 HPV and fertility.
D. Caserta
- 16.45-17.00 Potential innovations in cervical precancer management
W. Prendiville,
- 17.00-17.15 The role of oral contraception and hormone replacement therapy in HPV infection and disease.
F. Torcia
- 17.15-17.30 The ultrasound in the evaluation of preneoplastic and neoplastic lesions of the uterine cervix
U. Tabuica
- 17.30-17.40 Discussion

ROOM B**14.30-15.20 Pap Smear: Never Say Never Again****Chairpersons:** M. Benevolo - E. Carico

- 14.30-14.50 Don't forget me: cytology of HPV negative lesions.
G. Negri
- 14.50-15.10 What clinicians need from cytology.
W. Huh
- 15.10-15.20 Discussion

15.20-17.40 The Cervical Cytopathology in the HPV Testing Era**Coordinators:** M.R. Giovagnoli - G. Negri


An interactive seminar slide of cervical cytopathology.

ROOM A (Plenary session)**17.40-18.00 Presentation of the Best 3 Free Communications and Award for the Best****Chairpersons:** P. Davies - A. Frega - C. Gentili**18.00-18.10 General Discussion****18.10-18.20 ECM Test****18.20-18.30 Prize Giving for the Three Best Speakers and Conclusions**

GENERAL INFORMATION

EXHIBITION AREA

NH Hotel Villa Carpegna | ROMA



- 1. Cic Editore
- 2. Becton Dickinsons Italia
- 3. Farmitalia
- 4. Digi Medica Snc
- 5. Fujirebio Europe
- 6. IDI Pharma
- 7. Bio Stilogit Pharmaceuticals
- 8. S&R Farmaceutici
- 9. Smart
- 10. Morgan
- 11. Synlab Italia

- 12. Centrel
- 13. Difass International
- 14. Arrow Diagnostics
- 15. EuTylia
- 16. Sakura Italia
- 17. Roche Diagnostics
- 18. Depofarma
- 19. Hologic Italia
- 20. Farma-Derma
- 21. Verduci Editore

GENERAL INFORMATION

CONGRESS VENUE

NH Hotel Villa Carpegna
Via Pio VI, 6 | 00165 ROMA (RM) | Tel +39 06 393731
www.nh-hotels.it/hotel/nh-roma-villa-carpegna

LANGUAGE

English will be the official language of the Workshop.
Simultaneous translation into Italian will be provided.

ITALIAN ECM ACCREDITATION

The meeting will be accredited for the ECM credits for Italian doctors.
To obtain credits it is necessary to attend the meeting.
No promotional activities will be permitted in the same room before, during, or after an ECM activity.

The specialities and disciplines able to apply for Italian ECM credits are:

Medico Chirurgo: Anatomia Patologica; Igiene, Epidemiologia e Sanità Pubblica; Ginecologia e Ostetricia; Oncologia; Patologia Clinica (laboratorio di analisi chimico-cliniche e microbiologia)

Biologo: Anatomia Patologica; Igiene, Epidemiologia e Sanità Pubblica; Patologia Clinica (laboratorio di analisi chimico-cliniche e microbiologia)

Tecnico di laboratorio biomedico
Infermiere ed ostetrica

SPONSOR



Con il supporto non condizionante di
MSD ITALIA S.R.L. www.msd-italia.it



Patronage:

associazione
culturale
enead 



Organizing Secretariat:



Adria Congrex srl

Via Sassonia, 30 - 47922 Rimini

Tel. 0541.305873

c.imola@adriacongrex.it

www.hpvrrome.com

